Grifols (NASDAQ:GRFS) Shares Gap Down – Should You Sell?

Shares of Grifols, S.A. (NASDAQ:GRFS) gapped down prior to trading on Wednesday . The stock had previously closed at $8.05, but opened at $7.74. Grifols shares last traded at $7.92, with a volume of 144,627 shares changing hands.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Stock Performance

The stock has a 50-day moving average of $8.42 and a 200-day moving average of $8.11. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of 8.30 and a beta of 0.43.

Institutional Investors Weigh In On Grifols

A number of hedge funds and other institutional investors have recently bought and sold shares of GRFS. B. Riley Wealth Advisors Inc. bought a new position in shares of Grifols in the 2nd quarter worth $359,000. Sei Investments Co. raised its stake in shares of Grifols by 4.7% in the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after buying an additional 100,131 shares during the period. Melqart Asset Management UK Ltd purchased a new stake in Grifols during the third quarter valued at about $1,628,000. Hantz Financial Services Inc. bought a new position in Grifols in the 2nd quarter worth approximately $1,235,000. Finally, Verition Fund Management LLC purchased a new position in shares of Grifols in the third quarter valued at $2,636,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.